ES2161915T3 - Conjugados monofuncionales y/o polifuncionales de la polilisina. - Google Patents

Conjugados monofuncionales y/o polifuncionales de la polilisina.

Info

Publication number
ES2161915T3
ES2161915T3 ES95940329T ES95940329T ES2161915T3 ES 2161915 T3 ES2161915 T3 ES 2161915T3 ES 95940329 T ES95940329 T ES 95940329T ES 95940329 T ES95940329 T ES 95940329T ES 2161915 T3 ES2161915 T3 ES 2161915T3
Authority
ES
Spain
Prior art keywords
polylisine
conjugates
monofunctional
polyfunctional
invention refers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95940329T
Other languages
English (en)
Inventor
Michel Geffard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2161915T3 publication Critical patent/ES2161915T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION DE CONJUGADOS DE LA POLILISINA PARA LA PREPARACION DE COMPOSICIONES O ASOCIACIONES FARMACEUTICAS UTILES EN EL TRATAMIENTO DE LA DEGENERACION NEURONAL, DE LAS NEUROPATIAS INFECCIOSAS, TRAUMATICAS Y TOXICAS, DE LAS AFECCIONES DEGENERATIVAS DE CARACTER AUTOINMUNE Y DE LAS AFECCIONES PROLIFERATIVAS. LA INVENCION SE REFIERE TAMBIEN A CONJUGADOS DE LA POLILISINA.
ES95940329T 1994-11-18 1995-11-17 Conjugados monofuncionales y/o polifuncionales de la polilisina. Expired - Lifetime ES2161915T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9413861A FR2727117A1 (fr) 1994-11-18 1994-11-18 Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun

Publications (1)

Publication Number Publication Date
ES2161915T3 true ES2161915T3 (es) 2001-12-16

Family

ID=9468953

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95940329T Expired - Lifetime ES2161915T3 (es) 1994-11-18 1995-11-17 Conjugados monofuncionales y/o polifuncionales de la polilisina.

Country Status (14)

Country Link
US (1) US6114388A (es)
EP (1) EP0792167B1 (es)
JP (1) JP4128618B2 (es)
AT (1) ATE202487T1 (es)
AU (1) AU694825B2 (es)
CA (1) CA2205557C (es)
DE (1) DE69521521T2 (es)
DK (1) DK0792167T3 (es)
ES (1) ES2161915T3 (es)
FR (1) FR2727117A1 (es)
GR (1) GR3036710T3 (es)
NZ (1) NZ297040A (es)
PT (1) PT792167E (es)
WO (1) WO1996015810A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO104396A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Antiviral linear polymers
US6399071B1 (en) 1997-04-18 2002-06-04 Novartis Ag Neoglycoproteins
FR2763853B1 (fr) * 1997-05-28 2000-01-07 Oreal Association d'un retinoide avec un polymere polyamine
DE19732139C2 (de) 1997-07-25 2002-10-10 Max Planck Gesellschaft Mesomorphe Komplexe aus Vitamin A-Säure und kationischen Polyelektrolyten, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
FR2773808B1 (fr) * 1998-01-20 2000-05-05 Sagebo Composes susceptibles de pieger les ions metalliques, leur procede d'obtention et leur utilisation
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6686446B2 (en) * 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
GB9811059D0 (en) * 1998-05-23 1998-07-22 Univ Strathclyde Polyamino acid vesicles
ATE287278T1 (de) * 1998-07-30 2005-02-15 Sigma Tau Ind Farmaceuti Verwendung von propionyl-l-carnitin und acetyl-l- carnitin zur herstellung von arzneimittel mit antikrebs wirkung
AU4835200A (en) * 1999-05-10 2000-11-21 Regents Of The University Of California, The Methods and compositions for controlled polypeptide synthesis
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
EP2363710B1 (en) * 2002-08-08 2015-07-01 Baylor College Of Medicine Isolation and identification of T cells
DE60321363D1 (de) * 2002-08-28 2008-07-10 Millipore Corp Verfahren zur aufreinigung von sequenzierungsreaktionen
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
DK1868614T3 (da) 2005-03-24 2012-11-12 Univ Emory Dosisregime til behandling af en traumatisk hjerneskade med progesteron
FR2886153B1 (fr) * 2005-05-27 2009-04-10 Gemac Sa Composition destinee au traitement de la sclerose en plaques
CA2651328A1 (en) * 2006-05-05 2007-11-15 Opexa Therapeutics T-cell vaccine
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
ATE545436T1 (de) 2006-12-22 2012-03-15 Croma Pharma Ges M B H Verwendung von thiolierten polysacchariden zum gewebeaufbau
FR2913335B1 (fr) 2007-03-06 2009-06-05 Michel Geffard Utilisation de conjugues d'acides gras et de poly-l-lysine pour lutter contre des microorganismes pathogenes.
EP2085082A1 (en) * 2008-01-29 2009-08-05 Nutromnia S.R.L. Treatment of cognitive decline
CA2830970A1 (en) * 2011-04-12 2012-10-18 Nestec S.A. Nutritional compositions including branched chain fatty acids and methods of using same
HUE054034T2 (hu) 2014-03-13 2021-08-30 Univ Basel Mielin asszociált glikoprotein elleni IgM antitestekhez kapcsódó szénhidrát ligandumok
FR3030524B1 (fr) 2014-12-17 2017-01-20 Hydro-Fill Utilisation de pll pour ameliorer la stabilite de molecules en solution
WO2017046172A1 (en) 2015-09-16 2017-03-23 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
FR3048616B1 (fr) * 2016-03-14 2018-04-06 Polyneuros Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique
FR3122571B1 (fr) * 2021-05-10 2023-05-12 Hydro Fill Tech Compositions et leur utilisation pour rétablir la perméabilité intestinale et/ou prévenir ou lutter contre des maladies multifactorielles
FR3122573B1 (fr) * 2021-05-10 2024-03-29 Hydro Fill Tech Compositions de conjugués poly-lysine et de micelles et/ou de copolymères de poly-lysine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000515A1 (en) * 1978-01-16 1979-08-09 Univ Boston Method of effecting cellular uptake of molecules
DE3546150A1 (de) * 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
GB9004538D0 (en) * 1990-02-28 1990-04-25 Offord Robin E Chemical compounds
SG47099A1 (en) * 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
AU4534593A (en) * 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
FR2705234B1 (fr) * 1993-05-19 1995-08-04 Geffard Michel Utilisation de molécules reconnues par des autoanticorps de sérums humains pour le diagnostic ou le traitement du SIDA.

Also Published As

Publication number Publication date
US6114388A (en) 2000-09-05
FR2727117A1 (fr) 1996-05-24
CA2205557C (en) 2008-07-15
DK0792167T3 (da) 2001-10-29
AU4181196A (en) 1996-06-17
AU694825B2 (en) 1998-07-30
PT792167E (pt) 2001-12-28
DE69521521D1 (de) 2001-08-02
NZ297040A (en) 1999-05-28
GR3036710T3 (en) 2001-12-31
EP0792167B1 (fr) 2001-06-27
WO1996015810A1 (fr) 1996-05-30
JPH10511643A (ja) 1998-11-10
EP0792167A1 (fr) 1997-09-03
ATE202487T1 (de) 2001-07-15
DE69521521T2 (de) 2002-04-25
FR2727117B1 (es) 1997-02-21
JP4128618B2 (ja) 2008-07-30
CA2205557A1 (en) 1996-05-30

Similar Documents

Publication Publication Date Title
ES2161915T3 (es) Conjugados monofuncionales y/o polifuncionales de la polilisina.
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
ATE231872T1 (de) Thiazolopyrimidinderivate
DE69632256D1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
BR0011433A (pt) Imidazoquinolinas substituìdas com sulfonamida e sulfamida
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
MX9102353A (es) N,o-sulfados de heparosanos, su procedimiento de preparacion y las composiciones farmaceuticas que contienen.
PT1181027E (pt) Composicao dietetica ou farmaceutica para utilizacao na prevencao ou tratamento de hiperoxaluria
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
ES2181744T3 (es) Hidratos de paclitaxel cristalinos.
ATE100098T1 (de) Nukleoside, ihre herstellung und pharmazeutische zusammenstellungen.
PT767172E (pt) 8-arilalquil e 8-aril-heteroalquil-5, 11-di-hidro-6h-dipirido¬3,2-b:2' 3'-e| ¬1,4|diazepinas e a sua utilizacao na prevencao do tratamento da infeccao po hiv
SE9904377D0 (sv) Pharmaceutical combinations
ES2192704T3 (es) Innovadoras composiciones farmaceuticas.
NO990440L (no) Preparat som innbefatter mupirocin og klorheksidin
DE60021413D1 (de) Anti-virale zusammensetzung enthaltend ein palmaria palmata extrakt
FI971364A (fi) Kolkisiinijohdannaiset ja niiden terapeuttinen käyttö
BR0012184B1 (pt) compostos derivados de indol, formulação farmacêutica, e, composição e uso dos compostos na fabricação de medicamentos
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
ATE117724T1 (de) Antibiotikum ge 22270, faktoren a1,a2,a3 und h.
DK0451486T3 (da) Antibiotikum GE 2270 faktorer B1, B2, C1, C2, D1, D2, E og T
DE69403063D1 (de) Gegen viren wirksame naphtochinon-verbindungen, zusammensetzungen und deren verwendungen
BR9509925A (pt) Composição e uso da composição para prevenção ou tratamento de infecção por hiv-1

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 792167

Country of ref document: ES